Checking Out the Fundamental Data for Idera Pharmaceuticals, Inc. (IDRA)

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)’s interesting series of developments are underway around the US stock market these days. Now trading with a market value of 385.98M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For IDRA, the company currently has 63.94 million of cash on the books, which is offset by 285,000 in current liabilities. The trend over time is important to note. In this case, the company’s debt has been falling. The company also has 70.75 million in total assets, balanced by 8.67 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Idera Pharmaceuticals, Inc. (IDRA) saw -11.88 million in free cash flow last quarter, representing a quarterly net change in cash of -10.72 million. Perhaps most importantly where cash movements are concerned, the company saw about -11.88 million in net operating cash flow.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 164,000 in total revenues. That represents a quarterly year/year change in revenues of nan in sequential terms, the IDRA saw sales decline by nan.

But what about the bottom line? After all, that’s what really matters in the end. Idera Pharmaceuticals, Inc. (IDRA) is intriguing when broken down to its core data. For shareholders, given the total diluted outstanding shares of 149.64 million, this means overall earnings per share of -0.10. Note, this compares with a consensus analyst forecast of -0.09 in earnings per share for its next fiscal quarterly report.

Is Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.42 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Idera Pharmaceuticals, Inc..

Previous ArticleNext Article

Related Post

Twitter, Inc. (TWTR): Checking the Operational Dat... Twitter, Inc. (NYSE:TWTR) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market value of 32....
Fundamentals in Focus for Cognizant Technology Sol... Cognizant Technology Solutions Corporation (NASDAQ:CTSH) is an interesting stock at present. Now trading with a market value of 41.18B, the company ha...
Critical Comparison: Tanger Factory Outlet Centers... Tanger Factory Outlet Centers, Inc. (NYSE:SKT) and Simon Property Group, Inc. (NYSE:SPG) are the two most active stocks in the REIT - Retail industry ...
There Are Mixed Technical Signals in Yamana Gold I... Yamana Gold Inc. (NYSE:AUY) fell by -4.20% in Monday’s trading session from $2.86 to $2.74. The price has been moving in both directions for this peri...
The Fundamental Facts on American Campus Communiti... American Campus Communities, Inc. (NYSE:ACC) is one of the more popular stocks investors are adding into their watchlist. Now trading with a market va...